The Zivin et al. study has other methodological problems. The authors collapsed categories of a comorbidity index into one continuous covariate, altering magnitudes of comorbidity and increasing the possibility of data misinterpretation (3). Their study does not address whether particularly elevated risk exists in individuals with specific comorbid illnesses (e.g., heart failure)-those individuals targeted in the FDA warning. In addition, the person-time measure used by the authors permits more than one observation for the same individual during periods when different dosages were prescribed. In this situation, the possible group effects generated between different individuals and within the same individual in regression analyses should be examined; otherwise, the precision of regression estimates is compromised. Finally, contrary to the FDA warning, the authors concluded that no increase in risk of ventricular arrhythmia was associated with highdosage citalopram treatment without providing the theoretical explanation for their finding. Their results suggested that high-dosage antidepressants decreased the risk, although they avoided coming to that conclusion. Further study is needed to unravel the biological mechanisms underlying that finding.
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Adequate Dosing for Second-Generation Antipsychotics in Establishing Treatment Resistance in Schizophrenia
To the editor: Treatment resistance in schizophrenia requires evidence of two previous failed antipsychotic trials of 6 weeks at a dose of 600 mg in chlorpromazine equivalents (1) , while the original criteria for clozapine's role in treatment resistance stipulated a dose of 1,000 mg in chlorpromazine equivalents (2) .
Second-generation antipsychotics have largely supplanted their first-generation counterparts in the last decade, and studies have attempted to derive chlorpromazine equivalents for these agents either through expert consensus or calculation methods. This calls into question the impact of these different approaches on studies employing chlorpromazine equivalents.
The estimated doses of five commonly prescribed secondgeneration antipsychotics, using four widely used methods, are listed in Table 1 . Immediately apparent is the wide variation in calculated doses for any given second-generation antipsychotics; for example, at 600 mg of chlorpromazine equivalents, doses of risperidone vary between 6 mg and 12 mg and doses of aripiprazole vary between 24 mg and 45 mg. These differences are amplified at 1,000 mg of chlorpromazine equivalents.
At 1,000 mg of chlorpromazine equivalents, calculated doses for the second-generation antipsychotics uniformly exceed the maximum dosages currently recommended for these agents (3) . Even at 600 mg of chlorpromazine equivalents, values frequently lie outside the recommended dosage range. As importantly, the calculated doses differ markedly based on the method employed.
This variance raises practical considerations, for example, in declaring a failed second-generation antipsychotics trial in the process of defining treatment-resistant schizophrenia. The wide variation challenges the validity of using chlorpromazine equivalents to compare across antipsychotics. The reported near-maximal effective dose of chlorpromazine was 400-450 mg, not 600-1,000 mg, and there appears to be little evidence to support high doses in treatment-resistant schizophrenia (4). In addition, the high doses calculated raise serious safety concerns and fly in the face of regulatory dosing recommendations. Accordingly, adopting chlorpromazine equivalents may not be appropriate for evaluating an adequate dosage for specific second-generation antipsychotics, and we suggest that a more appropriate means to confirm a failed clinical trial is suboptimal response at the maximum recommended dosage range for a specific second-generation antipsychotics, as per product monograph. 
Metformin and Alzheimer's Disease Risk

Response to Rosenfeld
To the Editor: We appreciate Dr. Rosenfeld bringing attention to a recent report by Imfeld et al. (1) suggesting that long-term metformin use may increase the risk for Alzheimer's disease in elderly patients with diabetes mellitus. In fact, a number of clinical and preclinical reports within the past 5 (6) . e Doses calculated from power transformation for chlorpromazine equivalent (7). f Median (interquartile range) maximum doses (5) .
